🔬Nikon | News | Nikon Corporation and Yumanity Therapeutics Enter Contract for the Commission Development of Drug Discovery Assay System in Neurodegenerative Diseases
Nikon Corporation (President: Kazuo Ushida, Minato-ku, Tokyo) and its subsidiary Nikon Instruments Inc. (President: Toshiaki Nagano, Headquarters: Melville, NY, USA) and Yumanity Therapeutics[Open in a new window], a company focused on transforming drug discovery for diseases caused by protein misfolding, (CEO: Tony Coles, Headquarters: Massachusetts, USA (hereinafter “Yumanity Therapeutics”)) have concluded a contract (hereinafter “this contract”) which commissions the development of drug discovery assay systems in the field of neurodegenerative disease.
Nikon and Yumanity Therapeutics both seek to improve the quality of life of those suffering from these diseases by promoting the development of effective therapies.